Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Hanno Leuchte (Munich, Germany), Hanno Leuchte, Christoph Prechtl, Jens Callegari, Tobias Meis, Shani Haziraj, Dorian Bevec, Juergen Behr. Augmentation of the effects of vasoactive intestinal peptide aerosol on pulmonary hypertension via co-application of a neutral endopeptidase 24.11 inhibitor. Eur Respir J 2015; 46: Suppl. 59, 2435

Member's Comments

No comment yet.

Related content which might interest you: Inhalation of vasoactive intestinal peptide in pulmonary hypertension Source: Eur Respir J 2008; 32: 1289-1294 Year: 2008 Inhalation of vasoactive intestinal peptide in pulmonary hypertension Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008 Effect of POL6014, a protein epitope mimetic (PEM) neutrophil elastase inhibitor, in a model of monocrotaline (MCT)-induced pulmonary arterial hypertension in rats Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Effects of broad spectrum tyrosin kinase inhibitor on pulmonary circulation homeostasis Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 Selective inhibition of neutrophil elastase by BAY 85-8501 improves exercise capacity and pulmonary hypertension in a porcine pancreatic elastase-induced emphysema model Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors Source: International Congress 2016 – Clinic of pulmonary hypertension Year: 2016 Pathophysiology of pulmonary arterial hypertension Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=191 Year: 2004 Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 Effects of iloprost and the phosphodiesterase inhibitor tolafentrine on pulmonary vascular remodelling in chronic experimental pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 20s Year: 2003 Oral delivery of transplastomic plant derived angiotensin converting enzyme2 - a novel approach for pulmonary hypertension therapeutics Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Association of haemodynamic parameters with circulating natriuretic peptides in precapillary pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load Year: 2015 Effects of HIV protease inhibitors on monocrotaline-induced pulmonary hypertension in rats Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009 Expression vasoactive intestinal peptide and related receptors in overcirculation-induced pulmonary hypertension in piglets Source: Eur Respir J 2006; 28: Suppl. 50, 659s Year: 2006 Blunted effects of rho-kinase inhibitor, fasudil, on pulmonary arterial pressure in Yak, a high altitude-adapted animal Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Prevention of monocrotaline-induced pulmonary vascular and myocardial remodeling by the selective neutrophil elastase inhibitor BAY 85-8501 Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Biomarkers in pulmonary hypertension Source: Eur Respir J 2008; 32: 503-512 Year: 2008 Severe pulmonary hypertension in chronic lung disease. Long term effects on gas exchange of endothelin receptor antagonists or PDE5 inhibitors Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011 Vasoactive intestinal peptide (VIP) markedly attenuates pulmonary hypertension in fawn-hooded rats Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology Year: 2005 Prolonged activity of inhaled treprostinil prodrug nanoparticles in a rat model of pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Effects of a novel azaindole-based Rho-kinase inhibitor on hemodynamics and pulmonary vascular remodelling in experimental pulmonary hypertension Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009